Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. (Q30406342)

10 August 2017

Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. (English)

1 reference

10 August 2017

1

1 reference

10 August 2017

17

Razelle Kurzrock

1 reference

10 August 2017

Kaleb Yohay

27

0 references

Matthias A. Karajannis

object named as

Matthias Karajannis

15

0 references

Gideon Bollag

8

object named as

Gideon Bollag

1 reference

10 August 2017

4

Jaishri Blakeley

1 reference

10 August 2017

7

Allan Belzberg

1 reference

10 August 2017

2

Michel Kalamarides

1 reference

10 August 2017

3

Kim Hunter-Schaedle

1 reference

10 August 2017

9

Ruihong Chen

1 reference

10 August 2017

19

Andrea McClatchey

1 reference

10 August 2017

28

Marco Giovannini

1 reference

10 August 2017

Jeffrey Allen

5

1 reference

10 August 2017

Dusica Babovic-Vuskanovic

6

1 reference

10 August 2017

Emmanuelle DiTomaso

10

1 reference

10 August 2017

John Golfinos

11

1 reference

10 August 2017

Gordon Harris

12

1 reference

10 August 2017

Abraham Jacob

13

1 reference

10 August 2017

Ganjam Kalpana

14

1 reference

10 August 2017

Bruce Korf

16

1 reference

10 August 2017

Meng Law

18

1 reference

10 August 2017

Roger Packer

20

1 reference

10 August 2017

Pamela Roehm

21

1 reference

10 August 2017

Allan Rubenstein

22

1 reference

10 August 2017

William Slattery

23

1 reference

10 August 2017

James H Tonsgard

24

1 reference

10 August 2017

D Bradley Welling

25

1 reference

10 August 2017

Brigitte Widemann

26

1 reference

10 August 2017

language of work or name

English

0 references

publication date

11 August 2009

1 reference

10 August 2017

Clinical Cancer Research

1 reference

10 August 2017

15

1 reference

10 August 2017

16

1 reference

10 August 2017

5032-5039

1 reference

Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Contact-dependent inhibition of EGFR signaling by Nf2/Merlin

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Germline mutation of INI1/SMARCB1 in familial schwannomatosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Histological classification and molecular genetics of meningiomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Management of the patient and family with neurofibromatosis 2: a consensus conference statement

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Predictors of the risk of mortality in neurofibromatosis 2

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Multichannel auditory brainstem implant: update on performance in 61 patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Hearing preservation in neurofibromatosis type 2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Epidemiology and etiology of intracranial meningiomas: a review

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513640

Incidence and clinical features of asymptomatic meningiomas

26 November 2018

1 reference

12 December 2020

MRI evaluation of neurofibromatosis 2 patients: a standardized approach for accuracy in interpretation

1 reference

12 December 2020

Evaluation of clinical diagnostic criteria for neurofibromatosis 2

1 reference

12 December 2020

ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group

1 reference

12 December 2020

Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas

1 reference

12 December 2020

10.1158/1078-0432.CCR-08-3011

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

19671848

1 reference